Printer Friendly

EXOCELL ANNOUNCES PATENT

 PHILADELPHIA, Jan. 26 /PRNewswire/ -- Exocell, Inc., today announced that the U.S. Patent Office has allowed its patent covering unique cell lines that produce monoclonal antibodies targeted to glycated albumin. Exocell scientists are developing therapeutic and diagnostic products based on this technology for diabetes management applications.
 These antibodies allow for improved monitoring of diabetes management and for development of markers to detect the deleterious effects of diabetes on organ function and of intervention treatments to prevent complications of diabetes.
 Glycated albumin is formed when sugar reacts with albumin, the principal protein in blood. Formation of glycated albumin increases when the concentration of sugar in the blood increases. Diabetics have high levels of glycated albumin when diabetes is not well- controlled. Exocell's A717 monoclonal antibodies, covered by this patent, are the first that are uniquely targeted to the sugar part of albumin.
 "The increasing evidence that glycated albumin damages kidney cells gives the A717 antibodies, which can block these effects, important promise for the prevention of kidney failure in diabetes," said Dr. Rex Clements, vice president of medical affairs, Novo-Nordisk Pharmaceuticals Inc.
 Exocell's A717 monoclonal antibodies are part of a family of unique biologic agents that the company has developed for diagnostic and therapeutic applications. Earlier this year, Exocell gained allowance from the U.S. Patent Office for its E85 monoclonal antibodies to glycohemoglobin. Exocell also has gained FDA clearance for marketing its Glycaben test, based on the A717 technology, for diabetes management.
 -0- 1/26/93
 /NOTE: Glycaben is a registered trademark./
 /CONTACT: M.P. Cohen, M.D., scientific director, (press) 215-222-5515, or C.J. Newman, M.D., (companies or investors), 212-446-3306, both for Exocell/


CO: Exocell, Inc. ST: Pennsylvania IN: MTC SU:

DC -- DC004 -- 8980 01/26/93 10:05 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 26, 1993
Words:292
Previous Article:U.S. TECHNOLOGIES INC. ANNOUNCES LICENSING AGREEMENT AND NEW MANUFACTURING SOURCE
Next Article:PARAMAX PRESIDENT CHALLENGES SUPPLIERS TO SUPPORT COMPANY STRATEGIES IN SHRINKING DEFENSE MARKETPLACE
Topics:


Related Articles
PATENT OFFICE ALLOWS EXOCELL PATENT
EXOCELL WINS PATENT FOR DIABETIC KIDNEY DISEASE TREATMENT
NEW TREATMENT DISCOVERED TO PREVENT DIABETIC EYE DISEASE
CORTECS INTERNATIONAL AND EXOCELL SIGN FURTHER DIABETES COLLABORATION.
Exocell Developing New Treatment for Diabetic Kidney Disease
Exocell and Boehringer Mannheim Reach Settlement
Exocell Reports Positive Results of Phase II Clinical Trial with EXO-226 for Prevention of Diabetic Kidney Disease
Exocell Product Receives FDA Clearance
Exocell Receives Patents for Its Drug in Clinical Trials For Diabetic Kidney Disease.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters